Drugs / Betahistine
Betahistine
Trials 16
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 15 trials · 1 missed | ||||||
| Phase 1 | NCT05938517 | Jun → Oct 2021 | Meniere disease | Ludwig-Maximilians - University of Munich | Completed | No outcome recorded |
| Phase 1 | NCT01168336 | Jul → Dec 2010 | — | OBEcure Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00852956 | Feb → Apr 2009 | — | OBEcure Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT00829881 | Jan → Dec 2009 | attention deficit-hyperactivity disorder | P2D, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00459992 | Apr 2007 → Feb 2011 | obesity disorder | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | Missed primary |
| Phase 27 trials | ||||||
| Phase 2 | NCT07567274 | May → Jul 2026 overdue | tinnitus | Leading Edge Clinic | Enrolling by invitation | No outcome recorded |
| Phase 2 | NCT03908567 | Jul 2019 → Mar 2022 | peripheral vertigo | Auris Medical AG | Completed | No outcome recorded |
| Phase 2 | NCT00748436 | Sep 2008 → Apr 2009 | obesity disorder | OBEcure Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT00585585 | Jul 2007 → Jan 2011 | atypical depressive disorder | University of Cincinnati | Terminated | No outcome recorded |
| Phase 2 | NCT00466869 | May → Sep 2007 | hyperlipidemia | OBEcure Ltd. | Terminated | No outcome recorded Stop: Business |
| Phase 2 | NCT00428168 | Mar 2007 → Aug 2008 | — | OBEcure Ltd. | Terminated | No outcome recorded |
| Phase 2 | NCT00409305 | Jan → Jun 2007 | obesity disorder | OBEcure Ltd. | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT01468285 | Feb 2012 → Apr 2013 | — | Abbott Products | Completed | No outcome recorded |
| Phase 4 | NCT00160238 | Jan 2003 → ? | Meniere disease | Solvay Pharmaceuticals | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT03624283 | Sep 2018 → Dec 2019 | vestibular disorder | Eye & ENT Hospital of Fudan University | Unknown | No outcome recorded |
| — | NCT02026778 | Dec 2013 → Nov 2014 | — | Yonsei University | Completed | No outcome recorded |
| Comparator or background therapy6 trials | ||||||
| Phase 1/2 | NCT06001593 Background | Sep 2023 → Nov 2025 overdue | Meniere disease | Seoul National University Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT06544434 Background | May 2021 → Sep 2024 overdue | Meniere disease | Beijing Tongren Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT00709202 Comparator | Jul 2008 → May 2016 | autism spectrum disorder, bipolar I disorder, bipolar II disorder, schizoaffective disorder +2 | Nathan Kline Institute for Psychiatric Research | Completed | No outcome recorded |
| Phase 2/3 | NCT07435090 Comparator | Mar 2026 → Dec 2027 expected | peripheral vertigo | Shi Tianming | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07075289 Comparator | Apr → Aug 2024 | benign paroxysmal positional vertigo | Universitas Sebelas Maret | Completed | No outcome recorded |
| — | NCT07334002 Comparator | Mar → May 2026 overdue | tinnitus | Sisli Hamidiye Etfal Training and Research Hospital | Not yet recruiting | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2024-03-29 | Eisai Inc. | EISAI TO DIVEST RIGHTS FOR MERISLON® AND MYONAL® IN JAPAN TO KAKEN PHARMACEUTICAL eisai.com ↗ |
| 2022-11-07 | Eisai Inc. | EISAI TO DIVEST RIGHTS FOR MUSCLE RELAXANT MYONAL® AND VERTIGO AND EQUILIBRIUM DISTURBANCE TREATMENT MERISLON® IN ASIA TO DKSH eisai.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 22 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Betahistine | “Nasal spray solution with 5 mg/mL betahistine dihydrochloride. Administered three times daily as 1 spray per nostril. Total daily dose is 3 mg betahistine dihydrochloride.” NCT03908567 ↗ |
| Known as | Betahistine dihydrochloride | “Drug: Betahistine dihydrochloride” NCT05938517 ↗ |
| Known as | Betahistine Mesylate | “Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg, 3 times a day.” NCT06544434 ↗2“Comparing Oral Lumbrokinase DLBS1033 and Betahistine Mesylate in Benign Paroxysmal Positional Vertigo” NCT07075289 ↗ |
| Known as | Betaserc | “Betahistine 24 mg bid (Betaserc)” NCT00160238 ↗1“Betahistine 24 mg bid (Betaserc)” NCT07334002 ↗ |
| Known as | Merislon | “Betahistine Mesylate tablet (Merislon, Eisai Co., Ltd., China) with the treatment of 6 mg, 3 times a day.” NCT06544434 ↗ |
| Known as | MERTIGO SR | “betahistine mesylate (12 mg, MERTIGO SR tablet, Dexa Medica b.i.d.) for a 14-day prospective observation period.” NCT07075289 ↗ |
| Action | Activate | “Betahistine is a drug that activates histamine” NCT00829881 ↗ |
| Modality | Small molecule | “a histamine analog long used for the treatment of Meniere's disease, betahistine, that shows promise in reversing the antihistaminergic effects thought to be involved in...” NCT00709202 ↗ |
| Route | Oral | “Subjects take either betahistine (in one of three possible doses) or placebo capsules one time on the days of admission to the Clinical Center (day 1), three times on day 2 and...” NCT00459992 ↗ |